newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with